Business intelligence reports for the lab diagnostics industry
Subscribe for Exclusive Access.
Subscriptions & Reports
Interested in multiple copies or more than one of our G2 reports?
Call Sokha at 855-528-6903 or email spearson@g2intelligence.com to discuss pricing.
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
Emerging Tests: FDA Issues New Guidance on Using NGS Data to Secure Antiviral Drug & CDx Test Approval
...
Register
FDA Watch: Expanded Label Clearance Opens Cologuard to a Younger Market
September was an eventful month for one of the hottest products on the consumer genetic test market, the Cologuard multi-target stool DNA test (mtSDNA) for colorectal cancer screening produced by Exact Sciences. The month started badly with the release of a CMS-sponsored research report finding Cologuard “less effective and considerably more costly” than alternatives. Although Exact Sciences quickly criticized the report and its analytical methodology, its stock took a beating.
Industry Buzz: Cologuard’s Wild September Ride
...
Register
Testing Trends: AMP Creates New Quality Guidelines for PGx Laboratory Testing
...
Register
Test Utilization: New Guidelines Recommend Basing Routine Colorectal Cancer Screening on Risk Rather than Age
...
Register
Innovation: Breathalyzer May Offer Reliable, Easier Alternative to Blood-Based Opioid Detection
...
Register
Inside the Diagnostics Industry: Quest-hc 1 System Leverages Lab Data to Help Providers Monitor Test Utilization
...
Register
New Study Suggests Blood Testing May Be Capable of Diagnosing PTSD
...
Register
Mergers, Acquisitions & Asset Sales Analysis – September 2019
After a brief summer lull, strategic deal making ramped up in September, especially in alliance making where volume nearly doubled last month’s levels. Here’s an overview of the long-term trends and key deals from late August through the third week of September.
Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month
After a brief summer lull, strategic deal making ramped up in September, especially in alliance making where volume nearly doubled last month’s levels. Here’s an overview of the long-term trends and key deals from late August through the third week of September.